Companies / Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc.

Nasdaq: ATOSCIK 1488039SEATTLE, WAatossatherapeutics.com

Financials · FY2015

Revenue$1.8K
Net income$-34.77M
Total debt
Cash$26.09M
Diluted EPS$-4.04
Shares outstanding10.0M

Ownership

10.0M shares outstanding · as of Jul 31, 2026
1.6%Insiders
Ownership
Insiders1.61%161,038
Institutions5.07%505,866
Public float93.32%9,312,394

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Quay Steven CCEOPresident & CEO · Director
0.88%88,038
Daniel Mark JamesChief Financial Officer
0.63%63,000
0.10%10,000

Institutional holders 10

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 12, 2026Steinhart Richard I
Director
GrantCommon Stock$0+10K
10,000
0.10% of shares
low
Mar 26, 2026Daniel Mark James
Executive
GrantCommon Stock$0+63K
63,000
0.63% of shares
low
Mar 27, 2026Quay Steven C
CEO
GrantCommon Stock$0+65K
+282.14%
88,038
0.88% of shares
low
Jan 20, 2026Quay Steven C
CEO
GrantCommon Stock$0+325K
+2339.93%
339,101
3.40% of shares
low
Jan 20, 2026Quay Steven C
CEO
GrantCommon Stock$0+332K
+2386.49%
345,572
3.46% of shares
low
Jan 20, 2026Quay Steven C
CEO
GrantStock Options (right to buy)+950K
950,000
9.52% of shares
low
Jan 20, 2026Quay Steven C
CEO
GrantStock Options (right to buy)+950K
950,000
9.52% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ATOSCommon StockEquity04962H704BBG002NCD8C8